NYSE : QGEN
Qiagen N.V. — Key statistics
Healthcare · Diagnostics & Research · Netherlands
Last price 50.34 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 10.41B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 10.39B |
| Enterprise Value | 11.25B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | Jul 7, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | 206.80M |
| Shares Outstanding | 206.80M |
| Shares Change (YoY) | -0.20% |
| Shares Change (QoQ) | -0.53% |
| Owned by Insiders (%) | 0.60% |
| Owned by Institutions (%) | 85.65% |
| Float | 205.48M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 25.53 |
| Forward PE | 20.13 |
| PS Ratio | 4.94 |
| Forward PS | 4.76 |
| PB Ratio | 3.09 |
| P/TBV Ratio | 33.29 |
| P/FCF Ratio | 23.20 |
| P/OCF Ratio | 15.87 |
| PEG Ratio | 3.62 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 27.47 |
| EV / Sales | 5.35 |
| EV / EBITDA | 15.32 |
| EV / EBIT | 20.44 |
| EV / FCF | 25.12 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.85 |
| Quick Ratio | 2.05 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | 2.17 |
| Debt / FCF | 3.69 |
| Interest Coverage | 13.95 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 11.93% |
| Return on Assets (ROA) | 5.87% |
| Return on Invested Capital (ROIC) | 11.38% |
| Return on Capital Employed (ROCE) | 10.36% |
| Weighted Average Cost of Capital (WACC) | 6.83% |
| Revenue Per Employee | $381,884 |
| Profits Per Employee | $74,421 |
| Employee Count | 5,500 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 2.34 |
Taxes
| Measure | Value |
|---|
| Income Tax | 52.51M |
| Effective Tax Rate | 11.37% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.61 |
| 52-Week Price Change | +1.10% |
| 50-Day Moving Average | 45.11 |
| 200-Day Moving Average | 42.59 |
| Relative Strength Index (RSI) | 71.93 |
| Average Volume (20 Days) | 5,615,562 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.20M |
| Short Previous Month | 7.66M |
| Short % of Shares Out | 3.48% |
| Short % of Float | 3.51% |
| Short Ratio (days to cover) | 3.34 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 2.10B |
| Gross Profit | 1.39B |
| Operating Income | 550.06M |
| Pretax Income | 461.83M |
| Net Income | 409.32M |
| EBITDA | 734.19M |
| EBIT | 550.06M |
| Earnings Per Share (EPS) | $1.97 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 793.50M |
| Total Debt | 1.65B |
| Net Cash | -860.20M |
| Net Cash Per Share | -$4.16 |
| Equity (Book Value) | 3.36B |
| Book Value Per Share | 16.26 |
| Working Capital | 1.08B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 654.47M |
| Capital Expenditures | -206.77M |
| Depreciation & Amortization | 184.13M |
| Net Borrowing | 208.15M |
| Free Cash Flow | 447.70M |
| FCF Per Share | $2.16 |
Margins
| Measure | Value |
|---|
| Gross Margin | 66.38% |
| Operating Margin | 26.19% |
| Pretax Margin | 21.99% |
| Profit Margin | 19.49% |
| EBITDA Margin | 34.96% |
| EBIT Margin | 26.19% |
| FCF Margin | 21.32% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $2.76 |
| Dividend Yield | 5.50% |
| Dividend Growth (YoY) | 66.09% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 134.23% |
| FCF Payout Ratio | 121.95% |
| Buyback Yield | 0.20% |
| Shareholder Yield | 5.70% |
| Earnings Yield | 3.92% |
| FCF Yield | 4.31% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $49.02 |
| Price Target Difference | -2.39% |
| Analyst Consensus | Hold |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 4.34% |
| EPS Growth Forecast (3Y) | 6.50% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 8, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:1.05 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.8 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |